Form 4: Ventyx Biosciences Chief Scientific Officer Exercises Stock Options

John Nuss, Chief Scientific Officer of Ventyx Biosciences, exercised stock options to acquire a total of 198,934 shares of common stock at a price of $0.20 per share.

Summary

• John Nuss, the Chief Scientific Officer of Ventyx Biosciences, exercised stock options on December 10, 2024.
• He acquired 5,377 shares of common stock and 193,557 shares of common stock through the exercise of options.
• The exercise price for both sets of options was $0.20 per share.
• Following these transactions, Mr. Nuss directly owns 463,932 shares of Ventyx Biosciences common stock.
• The options were granted under the company's 2019 Equity Incentive Plan.
• The options vest monthly over a 36-month period from the vesting commencement dates of May 1, 2020 and February 6, 2019.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of stock option exercises by a key executive, which is generally a positive sign of confidence in the company. However, it is not a major event that would significantly impact the company's valuation.

Positives

• The exercise of stock options by a key executive like the Chief Scientific Officer can be seen as a positive sign of confidence in the company's future prospects.

Risks

• The document does not explicitly state any risks, but the exercise of options could potentially dilute existing shareholders' ownership if not managed carefully.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders exercise stock options. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• The vesting schedule of 36 months is a common practice in the biotech industry for stock options.
• The exercise price of $0.20 per share is not directly comparable without knowing the grant date fair value of the options.
• The number of shares acquired is specific to the individual and their compensation package, and not directly comparable to other companies.

Stakeholder Impact

• The exercise of stock options may have a minor dilutive effect on existing shareholders.

Key Dates

Keywords

stock options, Ventyx Biosciences, insider trading, equity incentive plan, Form 4, John Nuss, Chief Scientific Officer, share ownership